| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA861: Upadacitinib for treating active non-radiographic axial spondyloarthritis |
|
Medicine details |
|
| Medicine name | upadacitinib (Rinvoq®) |
| Formulation | 15 mg, 30 mg, 45 mg prolonged-release tablets |
| Reference number | 4653 |
| Indication | Treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs). |
| Company | AbbVie Ltd |
| BNF chapter | Immunological products & vaccines |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 02/08/2022 |
| NICE guidance | TA861: Upadacitinib for treating active non-radiographic axial spondyloarthritis |